ArticleGenetics in medicine open2026
Genome sequencing reveals the prevalence of Fabry disease-causing variants in Japan: Evidence from the Tohoku Medical Megabank.
Article in Genetics in medicine open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficient α-galactosidase A activity and characterized by multisystem involvement. Although considered rare, with reported prevalence ranging from 1 in 40,000 to 1 in 140,000, its true frequency in the general population remains uncertain. We aimed to determine the prevalence of FD-causing variants in a community-based cohort from the Tohoku Medical Megabank, Japan. Methods: Genome sequencing was performed in 68,615 individuals. Variant pathogenicity was classified according to American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines. Baseline demographics, serum α-galactosidase A (GLA) activity, plasma globotriaosylsphingosine, and self-reported health data were assessed. Results: Pathogenic GLA variants were identified in 4 individuals and a likely pathogenic variant in 1 individual (mean age 49.3 ± 15.9 years); all were female, corresponding to a prevalence of 1 in 13,723. All pathogenic variants were c.902G>A, associated with the cardiac phenotype, whereas the likely pathogenic variant was c.1076T>C. Mean plasma GLA activity was 5.64 ± 1.73 mmol/hr/mL in pathogenic variant carriers and 8.36 mmol/hr/mL in the likely pathogenic carrier. Plasma globotriaosylsphingosine levels were 3.7 ± 0.79 ng/mL and 0.96 ng/mL, respectively. Conclusion: Population based genome sequencing data suggest a higher prevalence of FD-causing variants in Japan than previously reported, highlighting potential underdiagnosis of late-onset FD in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.